Theravance Biopharma (NASDAQ:TBPH) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. Other research analysts have also recently issued reports about the company. Leerink Partners cut Theravance Biopharma from […]
More Stories
Boliden AB (publ) (OTCMKTS:BDNNY) Lifted to “Hold” at Berenberg Bank
Berenberg Bank upgraded shares of Boliden AB (publ) (OTCMKTS:BDNNY – Free Report) to a hold rating in a report issued...
Telia Company AB (publ) (OTCMKTS:TLSNY) Upgraded at BNP Paribas
BNP Paribas upgraded shares of Telia Company AB (publ) (OTCMKTS:TLSNY – Free Report) to a strong-buy rating in a research...
Telia Company AB (publ) (OTCMKTS:TLSNY) Upgraded at BNP Paribas
BNP Paribas upgraded shares of Telia Company AB (publ) (OTCMKTS:TLSNY – Free Report) to a strong-buy rating in a report...
General Mills (NYSE:GIS) Announces Earnings Results
General Mills (NYSE:GIS – Get Free Report) issued its earnings results on Wednesday. The company reported $1.07 earnings per share...
When is ‘Skull Island’ Season 2 coming? Know Everything Here!
Netflix has officially finalized the screenplays for Skull Island season 2. Originating in Legendary’s Monsterverse, Skull Island premiered a few...
Analysts Set Bausch Health Companies Inc. (NYSE:BHC) Price Target at $7.33
Bausch Health Companies Inc. (NYSE:BHC – Get Free Report) has received a consensus recommendation of “Hold” from the six research...